Table 1: Aggregate antibiograms of carbapenemase producing Enterobacterales and Pseudomonas isolates by number and percent susceptible to each antimicrobial, received by MDU PHL 01/01/2021 - 31/12/2022

**No isolates tested reported susceptibility to Ampicillin or Ampicillin/Sulbactam**

<table>
<thead>
<tr>
<th>Bacterial</th>
<th>Organism</th>
<th>Class A KPC-2</th>
<th>Class B OXA-23</th>
<th>Class C MBL</th>
<th>Class D VIM-1</th>
<th>Class D OXA-48</th>
<th>Class E IMP-1</th>
<th>Class F GIM-1</th>
<th>Class G NDM-1</th>
<th>Class H NDM-5</th>
<th>Class H NDM-7</th>
<th>Class I NDM-4</th>
<th>Class I NDM-5</th>
<th>Class I NDM-6</th>
<th>Class I NDM-7</th>
<th>Class I NDM-8</th>
<th>Class I NDM-9</th>
<th>Class I NDM-10</th>
<th>Class I OXA-23</th>
<th>Class I OXA-32</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoroquinolones</td>
<td>8/8 (100.0%)</td>
<td>5/5 (100.0%)</td>
<td>6/8 (75.0%)</td>
<td>6/8 (75.0%)</td>
<td>0/8 (0.0%)</td>
<td>0/6 (0.0%)</td>
<td>0/6 (0.0%)</td>
<td>6/8 (75.0%)</td>
<td>0/8 (0.0%)</td>
<td>6/8 (75.0%)</td>
<td>0/8 (0.0%)</td>
<td>6/8 (75.0%)</td>
<td>0/8 (0.0%)</td>
<td>6/8 (75.0%)</td>
<td>0/8 (0.0%)</td>
<td>6/8 (75.0%)</td>
<td>0/8 (0.0%)</td>
<td>6/8 (75.0%)</td>
<td>0/8 (0.0%)</td>
<td></td>
</tr>
</tbody>
</table>

**Note 1**: Aminoglycoside susceptible/resistance differentiates between organisms with and without acquired resistance mechanisms only. For systemic infections, aminoglycosides must be used in combination with other active therapy.

**Note 2**: Colistin susceptible/resistance differentiates between organisms with and without acquired resistance mechanisms only. For systemic infections, colistin must be used in combination with other active therapy.

**Total** | 160/202 (79.2%) | 88/201 (43.8%) | 66/202 (32.7%) | 98/202 (48.5%) | 7/8 (87.5%) | 5/201 (2.5%) | 5/5 (100.0%) | 5/172 (2.9%) | 5/182 (2.7%) | 6/8 (75.0%) | 0/8 (0.0%) | 4/5 (80.0%) | 5/5 (100.0%) | 6/6 (100.0%) | 6/6 (100.0%) | 6/8 (75.0%) | 5/5 (100.0%) | 6/6 (100.0%) | 6/6 (100.0%) |

**Legend**:
- *No interpretive criteria*
- *Intrinsic Resistance Reported*
- **Less than 4 isolates tested**
- *More than 20 isolates tested*

**Antibiogram of Carbapenemase Producing Organisms - March, 2023**